Home  |  Contact

Cellosaurus LIM1215 KRAS (G13D/+) (CVCL_LC82)

[Text version]

Cell line name LIM1215 KRAS (G13D/+)
Synonyms KRAS (G13D/+) LIM1215
Accession CVCL_LC82
Resource Identification Initiative To cite this cell line use: LIM1215 KRAS (G13D/+) (RRID:CVCL_LC82)
Comments Characteristics: Heterozygous knockin of a KRAS activating mutation.
Sequence variations Heterozygous for KRAS p.Gly13Asp (c.38G>A).
Heterozygous for ACVR2A p.Pro423Gln (c.1268C>A) and p.Lys437fs*5 (c.1310delA) (from parent cell line).
CTNNB1 p.Thr41Ala (c.121A>G) (from parent cell line).
Homozygous for TGFBR2 p.Lys128Serfs*35 (c.383delA) (from parent cell line).
Disease Colon adenocarcinoma (NCIt: C4349)
Lynch syndrome (NCIt: C8494)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 34Y
Category Cancer cell line
Web pages https://www.horizondiscovery.com/human-kras-g13d-lim1215-cell-line-hd-116-009

PubMed=22722830; DOI=10.1038/nature11156
Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., Valtorta E., Schiavo R., Buscarino M., Siravegna G., Bencardino K., Cercek A., Chen C.-T., Veronese S., Zanon C., Sartore-Bianchi A., Gambacorta M., Gallicchio M., Vakiani E., Boscaro V., Medico E., Weiser M., Siena S., Di Nicolantonio F., Solit D., Bardelli A.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Nature 486:532-536(2012)

Other Wikidata; Q54902525
Entry history
Entry creation22-Aug-2017
Last entry updated13-Nov-2018
Version number5